SUPN vs. PCRX, ARQT, INVA, CORT, ORIC, PHAT, KPTI, BTAI, PRGO, and AGIO
Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Pacira BioSciences (PCRX), Arcutis Biotherapeutics (ARQT), Innoviva (INVA), Corcept Therapeutics (CORT), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Karyopharm Therapeutics (KPTI), BioXcel Therapeutics (BTAI), Perrigo (PRGO), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Supernus Pharmaceuticals has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
Supernus Pharmaceuticals presently has a consensus target price of $41.00, indicating a potential upside of 36.35%. Pacira BioSciences has a consensus target price of $49.50, indicating a potential upside of 88.00%. Given Pacira BioSciences' higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.
Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals.
In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 3 articles in the media. Pacira BioSciences' average media sentiment score of 0.83 beat Supernus Pharmaceuticals' score of 0.64 indicating that Pacira BioSciences is being referred to more favorably in the news media.
99.7% of Pacira BioSciences shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Pacira BioSciences received 336 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.73% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has a net margin of 6.22% compared to Supernus Pharmaceuticals' net margin of 0.22%. Pacira BioSciences' return on equity of 12.81% beat Supernus Pharmaceuticals' return on equity.
Summary
Pacira BioSciences beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Supernus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Supernus Pharmaceuticals Competitors List
Related Companies and Tools
